

Name of the Issue: Vijaya Diagnostic Centre Limited

1 **Type of Issue** Initial Public Offer

2 **Issue Size (Rs. Mn)** 18,924.56*

**Source: Prospectus*

3 **Grade of issue along with name of the rating agency**

Name Not Applicable

Grade Not Applicable

4 **Subscription Level (Number of times)** 3.30*

Source: Basis of allotment

5 **QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%
(i) On Allotment *	30.94%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2021)	39.25%
(iii) at the end of 1st FY (March 31, 2022)	41.20%
(iv) at the end of 2nd FY (March 31, 2023)	39.48%
(v) at the end of 3rd FY (March 31, 2024)**	N.A.

**Shareholding pattern disclosed to Stock Exchanges*

*** QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 **Financials of the issuer**

(Rs. Million)

Parameters	1st FY (March 31, 2022)	2nd FY (March 31, 2023)	3rd FY (March 31, 2024) *
Income from operations	4,623.70	4,592.23	Not Available
Net Profit for the period	1,106.68	852.07	Not Available
Paid-up equity share capital	101.97	102.07	Not Available
Reserves / Other Equity	4,580.23	5,345.22	Not Available

** Financials not available as reporting for the relevant years has not been completed.*

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("**BSE**") and National Stock Exchange of India Limited ("**NSE**")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Nishant Sharma	Resignation
(ii) at the end of 2nd FY (March 31, 2023)	Sura Suprita Reddy	Appointed
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual utilization	Not applicable
(iii) Reasons for deviation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	531.00
Listing Date	14-Sep-21

Price parameters	At close of listing day- 14-Sep-2021	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2022)		
				Closing price	High	Low
Market Price	620.10	559.75	573.90	438.2	644.1	379.2
Nifty (since NSE is the designated exchange)	17,380.00	18,161.75	17,511.30	17,464.8	18,477.1	14,296.4
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2023)			As at the end of the 3rd FY after the listing of the issue (31st March, 2024)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	391.30	489.35	300.40	Not Available	Not Available	Not Available
Nifty	17,359.75	18,812.50	15,293.50	Not Available	Not Available	Not Available

* The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Company	As disclosed in offer document, at the end of FY 2021*	At the end of 1st FY (March 31, 2022)	At the end of 1st FY (March 31, 2023)	At the end of 1st FY (March 31, 2024)**
	Consolidated	8.26	10.76	8.16	Not Available
	Peer Group & Industry Avg	35.65	41.79	28.37	Not Available
	Dr. Lal Pathlabs	35.33	41.70	28.82	Not Available
	Metropolis Healthcare Limited	35.97	41.87	27.91	Not Available
P/E	Company				
	Consolidated	64.29	40.72	47.95	Not Available
	Peer Group & Industry Avg^	90.85	55.61	54.08	Not Available
	Dr. Lal Pathlabs	107.30	62.61	63.43	Not Available
	Metropolis Healthcare Limited	74.40	48.62	44.73	Not Available

RoNW	Company				
	Consolidated	23.64%	24%	15.64%	Not Available
	Peer Group & Industry Avg	24.67%	0.13	14.49%	Not Available
	Dr. Lal Pathlabs	23.42%	23%	14.47%	Not Available
	Metropolis Healthcare Limited	25.91%	2%	14.51%	Not Available
NAV per share	Company				
	Consolidated	35.23	46.09	53.37	Not Available
	Peer Group & Industry Avg	143.81	956.36	196.42	Not Available
	Dr. Lal Pathlabs	149.38	180.93	199.87	Not Available
	Metropolis Healthcare Limited	138.23	1,731.78	192.97	Not Available

Notes
* Sourced from Prospectus
**Not available as the relevant fiscal years have not been completed / information not disclosed
^ P/E is calculated as closing market price on NSE as on March 31, 2021 / Basic EPS for the year ended March 31, 2021 sourced from the Prospectus

14 Any other material information

Particulars	Date
Listing of equity shares of Vijaya Diagnostic Centre Ltd	14-Sep-21
Un-Audited Financial Results For The Second Quarter And Half Year Ended September 30, 2021.	8-Nov-21
Appointment of Company Secretary and Compliance Officer	8-Nov-21
Board Meeting Outcome for Outcome Of Board Meeting Held On November 8, 2021	8-Nov-21
Board Meeting Outcome for Outcome Of Board Meeting Held On February 4, 2022	4-Feb-22
Announcement under Regulation 30 (LODR)-Cessation	8-Mar-22
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended March 31,	26-May-22
Vijaya Diagnostic Centre Limited has informed the Exchange that Record date for the purpose of Dividend is 21-Sep-	30-Aug-22
Intimation Of Record Date For The Final Dividend For The Financial Year 2021-22	30-Aug-22
Unaudited Financial Results For The Second Quarter And Half Year Year Ended September 30, 2022	10-Nov-22
Announcement under Regulation 30 (LODR)-Change in Registered Office Address	10-Nov-22
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer	10-Nov-22
Clarification sought from Vijaya Diagnostic Centre Ltd	22-Dec-22
Appointment of Company Secretary and Compliance Officer	22-Dec-22
Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2022	13-Feb-23
Appointment of Company Secretary and Compliance Officer	13-Feb-23
Clarification sought from Vijaya Diagnostic Centre Ltd	28-Mar-23
Clarification On Increase In Volume	28-Mar-23
Clarification sought from Vijaya Diagnostic Centre Ltd	28-Apr-23
Clarification On Increase In Volume	28-Apr-23
Financial Results For The Q4 & FY 2023 (Standalone & Consolidated)	29-Apr-23
Corporate Action-Board approves Dividend	29-Apr-23
Announcement under Regulation 30 (LODR)-Change in Directorate	29-Apr-23
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s	29-Apr-23
Re-Appointment Of Cost Auditors Of The Company For The FY 2023-2024	29-Apr-23

Note: For further updates and information, please refer Stock Exchange websites